Institution
University of Louisville
Education•Louisville, Kentucky, United States•
About: University of Louisville is a education organization based out in Louisville, Kentucky, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 24600 authors who have published 49248 publications receiving 1573346 citations. The organization is also known as: UofL.
Topics: Population, Poison control, Transplantation, Cancer, Stem cell
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Compared signaling pathways activated by GDNF in two neuronal cell lines expressing different complements of GDNF receptors are compared to indicate the existence of novel signaling mechanisms directly or indirectly mediated by GFRα receptors acting in a cell-autonomous manner independently of Ret.
325 citations
••
TL;DR: Over a wide range of RV, increasing from 0 mL to >400 mL, the frequency of regurgitation and aspiration did not change appreciably, and bowel function scores did not correlate with the incidence of aspiration or Regurgitation.
Abstract: Background and Aims:Elevated residual volumes (RV), considered a marker for the risk of aspiration, are used to regulate the delivery of enteral tube feeding. We designed this prospective study to validate such use.Methods:Critically ill patients undergoing mechanical ventilation in the medical, cor
325 citations
••
TL;DR: It is concluded that PMPs modulate biological functions of hematopoietic cells and postulate that they play an important but as yet not fully understood role in intercellular cross-talk in hematoiesis.
325 citations
••
325 citations
••
Cleveland Clinic1, Washington University in St. Louis2, University of Manitoba3, Mayo Clinic4, University of California, San Francisco5, University of Kansas6, University of Louisville7, St. Luke's University Health Network8, University of Virginia9, Wayne State University10, University of Southern California11, Kaiser Permanente12, National Multiple Sclerosis Society13, Heart Rhythm Society14, American Academy of Neurology15, University of Calgary16
TL;DR: The development of a guideline covering 23 medications and 143 randomized trials, as well as 30-plus recommendations and multiple development steps, is complex to the point of being overwhelming.
Abstract: Objective To develop recommendations for disease-modifying therapy (DMT) for multiple sclerosis (MS). Methods A multidisciplinary panel developed DMT recommendations, integrating findings from a systematic review; followed an Institute of Medicine–compliant process to ensure transparency and patient engagement; and developed modified Delphi consensus–based recommendations concerning starting, switching, and stopping DMTs pertinent to people with relapsing-remitting MS, secondary progressive MS, primary progressive MS, and clinically isolated syndromes of demyelination. Recommendations were supported by structured rationales, integrating evidence from one or more sources: systematic review, related evidence (evidence not from the systematic review), principles of care, and inference from evidence. Results Thirty recommendations were developed: 17 on starting DMTs, including recommendations on who should start them; 10 on switching DMTs if breakthrough disease develops; and 3 on stopping DMTs. Recommendations encompassed patient engagement strategies and individualization of treatment, including adherence monitoring and disease comorbidity assessment. The panel also discussed DMT risks, including counseling about progressive multifocal leukoencephalopathy risk in people with MS using natalizumab, fingolimod, rituximab, ocrelizumab, and dimethyl fumarate; and made suggestions for future research to evaluate relative merits of early treatment with higher potency DMTs vs standard stepped-care protocols, DMT comparative effectiveness, optimal switching strategies, long-term effects of DMT use, definitions of highly active MS, and effects of treatment on patient-specified priority outcomes. This guideline reflects the complexity of decision-making for starting, switching, or stopping MS DMTs. The field of MS treatment is rapidly changing; the Academy of Neurology development process includes planning for future updates.
325 citations
Authors
Showing all 24802 results
Name | H-index | Papers | Citations |
---|---|---|---|
Robert M. Califf | 196 | 1561 | 167961 |
Aaron R. Folsom | 181 | 1118 | 134044 |
Yang Gao | 168 | 2047 | 146301 |
Stephen J. O'Brien | 153 | 1062 | 93025 |
James J. Collins | 151 | 669 | 89476 |
Anthony E. Lang | 149 | 1028 | 95630 |
Sw. Banerjee | 146 | 1906 | 124364 |
Hermann Kolanoski | 145 | 1279 | 96152 |
Ferenc A. Jolesz | 143 | 631 | 66198 |
Daniel S. Berman | 141 | 1363 | 86136 |
Aaron T. Beck | 139 | 536 | 170816 |
Kevin J. Tracey | 138 | 561 | 82791 |
C. Dallapiccola | 136 | 1717 | 101947 |
Michael I. Posner | 134 | 414 | 104201 |
Alan Sher | 132 | 486 | 68128 |